382 related articles for article (PubMed ID: 35450967)
1. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
[TBL] [Abstract][Full Text] [Related]
2. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Schindler SE; Bollinger JG; Ovod V; Mawuenyega KG; Li Y; Gordon BA; Holtzman DM; Morris JC; Benzinger TLS; Xiong C; Fagan AM; Bateman RJ
Neurology; 2019 Oct; 93(17):e1647-e1659. PubMed ID: 31371569
[TBL] [Abstract][Full Text] [Related]
3. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
4. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
[TBL] [Abstract][Full Text] [Related]
5. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
Huang Y; Li Y; Xie F; Guo Q
CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
7. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors.
Hajjar I; Yang Z; Okafor M; Liu C; Waligorska T; Goldstein FC; Shaw LM
JAMA Netw Open; 2022 Oct; 5(10):e2235068. PubMed ID: 36201209
[TBL] [Abstract][Full Text] [Related]
8. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
[TBL] [Abstract][Full Text] [Related]
9. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
[TBL] [Abstract][Full Text] [Related]
10. Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.
McCarter SJ; Lesnick TG; Lowe VJ; Rabinstein AA; Przybelski SA; Algeciras-Schimnich A; Ramanan VK; Jack CR; Petersen RC; Knopman DS; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Graff-Radford J
J Alzheimers Dis; 2022; 87(4):1537-1547. PubMed ID: 35527558
[TBL] [Abstract][Full Text] [Related]
11. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
[TBL] [Abstract][Full Text] [Related]
12. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
13. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
Li Y; Schindler SE; Bollinger JG; Ovod V; Mawuenyega KG; Weiner MW; Shaw LM; Masters CL; Fowler CJ; Trojanowski JQ; Korecka M; Martins RN; Janelidze S; Hansson O; Bateman RJ
Neurology; 2022 Feb; 98(7):e688-e699. PubMed ID: 34906975
[TBL] [Abstract][Full Text] [Related]
14. Association of β-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
Cai Y; Shi D; Lan G; Chen L; Jiang Y; Zhou L; Guo T;
Neurology; 2024 Apr; 102(7):e209205. PubMed ID: 38489560
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
17. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
[TBL] [Abstract][Full Text] [Related]
19. Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
Ramanan VK; Graff-Radford J; Syrjanen J; Shir D; Algeciras-Schimnich A; Lucas J; Martens YA; Carrasquillo MM; Day GS; Ertekin-Taner N; Lachner C; Willis FB; Knopman DS; Jack CR; Petersen RC; Vemuri P; Graff-Radford N; Mielke MM
Neurology; 2023 Oct; 101(14):e1402-e1411. PubMed ID: 37580163
[TBL] [Abstract][Full Text] [Related]
20. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
Stevenson-Hoare J; Heslegrave A; Leonenko G; Fathalla D; Bellou E; Luckcuck L; Marshall R; Sims R; Morgan BP; Hardy J; de Strooper B; Williams J; Zetterberg H; Escott-Price V
Brain; 2023 Feb; 146(2):690-699. PubMed ID: 35383826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
